Application

It may be used as 3β-hydroxysterol-Δ²⁴-reductase (DHCR24) inhibitor.

DMHCA has been used as LXR activator to treat retinal endothelial cells in order to activate the sirtuin 1- liver X receptors (SIRT1-LXR) pathway.

Biochem/physiol Actions

DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is a synthetic oxysterol and is an agonist for liver X receptors (LXR). It promotes cholesterol transport, expression of adenosine triphosphate (ATP) binding cassette transporters. DMHCA suppresses the proinflammatory cytokines stimulation, induced by oxysterol.

N,N-dimethyl-3β-hydroxycholenamide (DHMCA) halts cholesterol biosynthesis by inhibiting 3β-hydroxysterol-Δ²⁴-reductase (DHCR24) enzyme. It may serve as a therapeutic agent for treating atherosclerosis, age-related macular degeneration and diabetic retinopathy.

General description

N,N-dimethyl-3β-hydroxy-cholenamide (DMHCA) is a potent steroidal liver X receptor (LXR) ligand in vitro and in vivo. It is used to treat atherosclerosis.

N,N-dimethyl-3β-hydroxycholenamide (DHMCA) is a synthetic ligand for liver X receptor (LXR).

Packaging

5 mL Amber Glass Screw Cap Vial (700125P-5mg)